Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Arrhythmia
67%
Atrial Fibrillation
60%
Catheter Ablation
50%
Acute Myocardial Infarction
40%
Cardiac Resynchronization Therapy
39%
Diabetes
38%
Large Vegetation
38%
Lead Extraction
38%
Cardiac Contractility Modulation
38%
Radiofrequency Catheter Ablation
38%
Atrial Fibrillation Arrhythmia
38%
Collateral Damage
38%
Stellate Ganglion Blockade
38%
Electrical Storm
38%
Single-center Experience
38%
Vacuum Delivery
38%
Historical Cohort Study
38%
Cardiac Implantable Electronic Device
38%
Management Considerations
38%
Debulking
38%
Ventricular Arrhythmia
38%
Persistent Left Superior Vena Cava (PLSVC)
38%
Acute Decompensated Heart Failure
38%
Pulsed Field Ablation
38%
Watchman Device
38%
Pulmonary Vein Isolation
38%
Symptomatic Atrial Fibrillation
38%
Cardiac Sarcoidosis
38%
Retrospective Analysis
38%
Ventricular Tachycardia
38%
Propensity Score Matching
38%
Ejection Fraction
28%
New-onset Atrial Fibrillation
28%
Patients with Diabetes Mellitus
22%
Type 1 Diabetes Mellitus (T1DM)
22%
Guideline-directed Medical Therapy
22%
Defibrillation
21%
Myocardial Infarction
19%
Post-myocardial Infarction
19%
High Risk
17%
Device Implantation
16%
Heart Failure
16%
Hyperglycemia
15%
T-wave Alternans
15%
Myocardium
15%
Mortality Rate
13%
Cardiogenic Shock
13%
Endocardium
12%
Tachyarrhythmia
12%
Anatomical Structure
12%
Medicine and Dentistry
Cardiac Dysrhythmia
80%
Atrial Fibrillation
77%
Ventricular Tachycardia
76%
Radiofrequency Ablation
76%
Congestive Heart Failure
41%
Acute Heart Infarction
40%
Cardiac Resynchronization Therapy
38%
Lead Extraction
38%
Heart Muscle Contractility
38%
Persistent Left Superior Vena Cava
38%
Prevalence
38%
Debulking
38%
Cardiac Sarcoidosis
38%
Heart Conduction
38%
Tachycardia
38%
Anatomical Concepts
38%
Scar Tissue
38%
Epicardium
38%
Endocardium
38%
Electrical Storm
38%
Pulsed Field Ablation
38%
Pulmonary Vein Isolation
38%
Cohort Analysis
38%
Stellate Ganglion Block
38%
Electrography
38%
Ejection Fraction
31%
Myocardial Infarction
30%
New-Onset Atrial Fibrillation
22%
Defibrillation
21%
Apoplexy
20%
Ablation Therapy
19%
Antiarrhythmic Drug
16%
Assisted Ventilation
12%
Tachyarrhythmia
12%
Heart Disease
12%
Cardiogenic Shock
11%
Defibrillator
11%
Fluoroscopy
10%
Brain Ischemia
10%
Dexamethasone
8%
Recurrent Disease
7%
Experimental Therapy
7%
Gene Expression
7%
Clinical Trial
7%
Coronary Angiography
7%
Acute Coronary Syndrome
7%
Combination Therapy
7%
Quality of Life
7%
Percutaneous Coronary Intervention
7%
Tamponade
7%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Arrhythmia
100%
Atrial Fibrillation
77%
Congestive Heart Failure
41%
Acute Heart Infarction
40%
Prevalence
38%
Heart Ventricle Arrhythmia
38%
Cohort Study
38%
Diabetes Mellitus
38%
Heart Ventricle Tachycardia
38%
Cardiac Sarcoidosis
38%
Antiarrhythmic Drug
38%
Heart Infarction
30%
New-Onset Atrial Fibrillation
22%
Dexamethasone
19%
Randomized Controlled Trial
14%
Cardiogenic Shock
11%
Brain Ischemia
10%
Ropivacaine
9%
Anticoagulant Agent
9%
Bupivacaine
9%
Hypotension
9%
Local Anesthetic Agent
9%
Hyperglycemia
9%
Lidocaine
9%
Cardiovascular Disease
9%
Acute Coronary Syndrome
7%
Combination Therapy
7%
Recurrent Disease
7%
Clinical Trial
7%
Cerebrovascular Accident
7%